ZHANGZHOU PIENTZEHUANG PHARMS.'A' sees a downgrade to Slightly Negative on account of less fundamental stars
The independent financial analyst theScreener just lowered the general evaluation of ZHANGZHOU PIENTZEHUANG PHARMS.'A' (CN), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date January 7, 2022, the closing price was CNY 394.31 and its target price was estimated at CNY 327.99.Zhangzhou Pientzehuang Pharmaceutical is engaged in the manufacture of pastille, tablets, granule, capsule, ointment, syrup, tincture, decoct ointment, and pill; the manufacture and sale of Pientzehuang royal jelly capsule and Liyan Buccal tablets; the import of production necessary auxiliary materials equipment and related technology; undertaking of China and foreign countries joint ventures and cooperation in production; undertaking the processing of materials, sample and assembling parts supplied by clients; and develop compensation trading. Co. primarily provides Pienzehuang series products for pain-inhibition, anti-inflammation and detoxification and curing hepatitis.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.